

Haematologica
HAEMATOL/2019/222059
Version 2

Proposed diagnostic criteria for classical CMML, CMML variants and
pre-CMML conditions

Peter Valent, Attilio Orazi, Michael R. Savona, Mrinal M. Patnaik,
Francesco Onida, Arjan A. van de Loosdrecht, Detlef Haase, Torsten
Haferlach, Chiara Elena, Lisa Pleyer, Wolfgang Kern, Tea Pemovska,
Gregory I. Vladimer, Julie Schanz, Alexandra Keller, Michael Lubbert,
Thomas Lion, Karl Sotlar, Andreas Reiter, Theo De Witte, Michael
Pfeilstocker, Klaus Geissler, Eric Padron, Michael Deininger, Alberto
Orfao, Hans-Peter Horny, Peter L. Greenberg, Daniel A. Arber, Luca
Malcovati, and John M. Bennett

Disclosures: The authors declare that they have no conflict of interest in this study and paper. Conflicts of interest (past 3 years) outside the study are as follows: P.V.: Research grant: Celgene, Incyte, Pfizer; Honoraria (Advisory Board, Speaker): Celgene, Novartis, Incyte, Pfizer, Deciphera A.Ora.: no conflict of interest M.R.S.: Research grant: Astex, Incyte, Takeda, TG Therapeutics; Equity: Karyopharm; Honoraria (Advisory Board, Speaker, Consultant): Amgen, Celgene, Incyte, Karyopharm, Selvita, Takeda, TG Therapeutics; Data safety monitoring boards: Celgene, Gilead, TG Therapeutics M.M.P.: Honoraria (Advisory Board): Stem Line Pharmaceuticals F.O.: no conflict of interest A.A.v.d.L.: no conflict of interest D.H.: Honoraria (Advisory Board, Speaker): Celgene, Novartis, BMS, Takeda; research grants: Celgene, Novartis T.H.: no conflict of interest C.E.: Honoraria (Advisory Board, Speaker): Novartis, Pfizer, Incyte L.P.: Honoraria (Advisory Board, Speaker): Celgene, Novartis, Abbvie W.K.: Equity ownership of MLL Munich Leukemia Laboratory T.P.: no conflict of interest G.I.V.: Shareholder and employee of Allcyte GmbH J.S.: Honoraria (Speaker): Novartis A.K.: no conflict of interest M.L.: Research Support: Janssen-Cilag; Honoraria (Advisory Board) Astex Pharma, Hexal T.L.: Research grant: Incyte; Honoraria (Advisory Board, Speaker): Chimerix, Incyte, Angelini, Pfizer. K.S.: Honoraria (Advisory Board, Consultant): BMS, Novartis, Pfizer, Nanostring A.R.: Honoraria (Advisory Board, Consultant): Novartis, Blueprint, Deciphera, Incyte, CTI Biopharma T.d.W.: no conflict of interest M.P.: Honoraria (Advisory Board, Speaker): Celgene, Jazz, Novartis, Sanofi K.G.: Honoraria (Advisory Board, Speaker): Abbvie, Amgen, Astra, AOP, BMS, Celgene, Jazz, MSD, Novartis, Pfizer, Ratiopharm, Roche, Sandoz, Sanofi E.P.: Research grant: Celgene, Incyte, Kura, and KaloBios; Honoraria (Advisory Board, Speaker): Celgene, Incyte, Aceleron M.D.: Honoraria (Advisory Board, Consultant): Novartis, Pfizer, BMS, Incyte, CTBio, Blueprint, Galena, Ascentage A.Orf.: Research grant: Cytognos, Immunostep, Becton-Dickinson; Honoraria (Advisory Board, Consultant, Speaker): Janssen, Novartis, Cytognos, Amgen, Alexion, Becton-Dickinson; Share-holder: 300k Biotech Solutions; Patents: Inventor of University of Salamanca, and EuroFlow owned patents licensed to Cytognos, Immunostep, Fagotrace and Becton-Dickinson, that return royalties to University of Salamanca and EuroFlow. H.P.H.: Honoraria (Advisory Board, Consultant): Novartis, Deciphera, Blueprint P.G.: Research grant: Celgene, Genentech, H3 Biotech, Notable Labs; Honoraria (Advisory Board): Novartis D.A.A.: no conflict of interest L.M.: no conflict of interest J.M.B.: no conflict of interest

Contributions: All co-authors contributed by establishing concepts and recommendations, by participating in the pre-conference and post-conference discussion-phases, by actively participating in the Working Conference, by formulating consensus statements, by writing parts of the manuscript, and by correcting the draft and approving the final version of the document. Consensus statements were based on a 100% agreement (all faculty members agreed) and only those statements were included in this article.